NCT04987229Enrolling by invitationPhase 3
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Source: ClinicalTrials.gov · Last updated 14 Aug 2026
Brief summary (registry, in English)
To evaluate the long-term safety and tolerability of OLZ/SAM in pediatric subjects with schizophrenia or Bipolar I disorder
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 236 (estimated)
- First submitted
- 26 Jul 2021
- Start date
- 22 Oct 2021
- Primary completion date
- Sept 2027
- Lead sponsor
- Alkermes, Inc.
- Diseases
- Schizophrenia, Bipolar disorder
- NCT number
- NCT04987229
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 236
- From 22 Oct 2021 to the primary completion date, Sept 2027
- 33 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Subject is currently taking medications that are contraindicated with olanzapine use or exhibit drug-interaction potential with olanzapine
- Subject has a positive urine pregnancy test, is currently pregnant or breastfeeding, or plans to become pregnant or begin breastfeeding at any point during the study and for 90 days after any study drug administration.
Other
- Subject poses a current suicide risk as assessed by the Investigator or as confirmed by the baseline Columbia-Suicide Severity Rating Scale by a response of "Yes" to question numbers 4 or 5 with ideation or suicidal behavior since the last visit.
- Subject has any finding that in the view of the Investigator or Medical Monitor would compromise the safety of the subject or affect their ability to fulfill the protocol visit schedule or visit requirement.
- Subject has a positive test for opioids.
Who the study is looking for
- Subject has completed the treatment period in either the ALKS 3831-A311 or the ALKS 3831-A312 study within 10 days of enrolling into this extension study, or subject had terminated early from Study ALKS 3831-A312 due to the clinically significant weight gain criterion.
- Subject will benefit from continued therapy with OLZ/SAM per clinical judgment.
- Subject is able to be treated on an outpatient basis.
- Subject must not be a danger to self or others (per Investigator judgement) and has family support available to be maintained as an outpatient.
- Subject's parent(s)/legal guardian(s) is considered reliable by the Investigator and has agreed to provide support to the subject to ensure compliance with study treatment, visits, and protocol procedures.
- Subject agrees to abide by the contraception requirements specified in the protocol for the duration of the study.
Age in the registry: 10 years to 17 years · Sex: All · Does not accept healthy volunteers
Sites (33)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.